-
公开(公告)号：US09364525B2
公开(公告)日：2016-06-14
申请号：US12374238
申请日：2007-07-16
Applicant: Joseph D. Cohen , Martine Marchand , Christian F. Ockenhouse , Anjali Yadava
Inventor： Joseph D. Cohen , Martine Marchand , Christian F. Ockenhouse , Anjali Yadava
IPC: A61K39/015 , A61K39/00 , C07K14/445 , C12N7/00
CPC classification number: A61K39/015 , A61K2039/6075 , C07K14/445 , C07K2319/40 , Y02A50/412
Abstract: The present invention relates to a novel lipoprotein particle, methods for preparing and purifying the same, its use in medicine, particularly in the prevention of malarial infections, compositions/vaccines containing the particle or antibodies against the protein particle such as monoclonal or polyclonal antibodies and use of the same, particularly in therapy. In particular it relates to an immunogenic protein particle comprising the following monomers: a. a fusion protein comprising sequences derived from a CS protein of P. vivax and the S antigen of Hepatitis B (CSV-S), and b. a fusion protein comprising sequences derived from CS protein of P. falciparum and S antigen of Hepatitis B (RTS), and c. optionally the S antigen derived from Hepatitis B.
Abstract translation: 本发明涉及一种新的脂蛋白颗粒，其制备和纯化方法，其在医学中的用途，特别是在预防疟疾感染中，含有颗粒的组合物/疫苗或针对蛋白质颗粒的抗体，例如单克隆或多克隆抗体，以及 使用相同，特别是在治疗中。 尤其涉及包含以下单体的免疫原性蛋白质颗粒：a。 包含源自间日疟原虫的CS蛋白的序列和乙型肝炎的S抗原（CSV-S）的融合蛋白，以及b。 包含衍生自恶性疟原虫的CS蛋白和乙型肝炎（RTS）的S抗原的序列的融合蛋白，以及c。 任选地来自乙型肝炎的S抗原。
-
公开(公告)号：US20130216613A1
公开(公告)日：2013-08-22
申请号：US13879438
申请日：2011-10-14
Applicant: Guy Jean Marie Fernand Pierre Baudoux , Normand Blais , Martine Marchand
IPC: A61K39/245 , C07K14/03
CPC classification number: A61K39/245 , A61K39/12 , A61K2039/55555 , A61K2039/55572 , A61K2039/55577 , C07K14/005 , C07K14/03 , C12N2710/16122 , C12N2710/16134
Abstract: The invention relates to a cytomegalovirus (CMV) gB polypeptide comprising at least a portion of a gB protein extracellular domain comprising a fusion loop 1 (FL1) domain and a fusion loop 2 (FL2) domain, wherein at least one of the FL1 and FL2 domains comprises at least one amino acid deletion or substitution.
Abstract translation: 本发明涉及包含至少一部分包含融合环1（FL1）结构域和融合环2（FL2）结构域）的gB蛋白细胞外结构域的巨细胞病毒（CMV）gB多肽，其中FL1和FL2中的至少一个 结构域包含至少一个氨基酸缺失或取代。
-
公开(公告)号：US20100272788A1
公开(公告)日：2010-10-28
申请号：US12810364
申请日：2008-12-22
Applicant: Joseph D. Cohen , Martine Marchand
Inventor： Joseph D. Cohen , Martine Marchand
CPC classification number: C07K14/445 , A61K39/015 , A61K2039/5258 , A61K2039/55555 , A61K2039/55566 , A61K2039/55572 , A61K2039/55577 , A61K2039/6075 , C07K2319/40 , C12N7/00 , C12N2730/10123 , Y02A50/412
Abstract: The present invention relates to a novel lipoprotein particle, methods for preparing and purifying the same, its use in medicine, particularly in the prevention of malarial infections, compositions/vaccines containing the particle or antibodies against the protein particle such as monoclonal or polyclonal antibodies and use of the same, particularly in therapy. Furthermore, particles with the specific ratio can be prepared by employing yeast, Saccharomyces cerevisiae or Pichia pastoris. In particular it relates to an immunogenic protein particle comprising the following monomers: a. a fusion protein comprising sequences derived from a CS protein of P. vivax and the S antigen of Hepatitis B (CSV-S), and b. S antigen derived from Hepatitis B virus, and characterised in that the ratio of S to CSV-S is in the range 0.1 to 1. Suitably, the ratio of S to CSV-S is in the range 0.19 to 0.30 or 0.68 to 0.80.
Abstract translation: 本发明涉及一种新的脂蛋白颗粒，其制备和纯化方法，其在医学中的用途，特别是在预防疟疾感染中，含有颗粒的组合物/疫苗或针对蛋白质颗粒的抗体，例如单克隆或多克隆抗体，以及 使用相同，特别是在治疗中。 此外，具有特定比例的颗粒可以通过使用酵母，酿酒酵母或巴斯德毕赤酵母来制备。 尤其涉及包含以下单体的免疫原性蛋白质颗粒：a。 包含源自间日疟原虫的CS蛋白的序列和乙型肝炎的S抗原（CSV-S）的融合蛋白，以及b。 S抗原来自乙型肝炎病毒，其特征在于S与CSV-S的比例在0.1〜1范围内.S与CSV-S的比例在0.19〜0.30或0.68〜0.80的范围内。
-
公开(公告)号：US20090053291A1
公开(公告)日：2009-02-26
申请号：US11927793
申请日：2007-10-30
Applicant: Claudine BRUCK , Stephane Andre Georges Godart , Martine Marchand
Inventor： Claudine BRUCK , Stephane Andre Georges Godart , Martine Marchand
CPC classification number: C07K14/005 , A61K39/00 , A61K39/12 , A61K39/21 , A61K2039/55572 , A61K2039/55577 , A61K2039/6068 , C07K2319/00 , C12N2740/16322 , C12N2740/16334
Abstract: The invention provides (a) an HIV Tat protein or derivative thereof linked to either (i) a fusion partner or (ii) an HIV Nef protein or derivative thereof; or (b) an HIV Nef protein or derivative thereof linked to either (i) a fusion partner or (ii) an HIV Tat protein or derivative thereof; or (c) an HIV Nef protein or derivative thereof linked to an HIV Tat protein or derivative thereof and a fusion partner. The invention further provides for a nucleic acid encoding such a protein and a host cell, such as Pichia Pastoris, transformed with the aforementioned nucleic acid.
Abstract translation: 本发明提供（a）与（i）融合伴侣或（ii）HIV Nef蛋白或其衍生物连接的HIV Tat蛋白或其衍生物; 或（b）与（i）融合伴侣或（ii）HIV Tat蛋白或其衍生物连接的HIV Nef蛋白或其衍生物; 或（c）与HIV Tat蛋白或其衍生物和融合配偶体连接的HIV Nef蛋白或其衍生物。 本发明进一步提供了用上述核酸转化的编码这种蛋白质和宿主细胞如毕赤酵母的核酸。
-
公开(公告)号：US20080102080A1
公开(公告)日：2008-05-01
申请号：US11927783
申请日：2007-10-30
Applicant: Claudine BRUCK , Stephane GODART , Martine MARCHAND
Inventor： Claudine BRUCK , Stephane GODART , Martine MARCHAND
CPC classification number: C07K14/005 , A61K39/00 , A61K39/12 , A61K39/21 , A61K2039/55572 , A61K2039/55577 , A61K2039/6068 , C07K2319/00 , C12N2740/16322 , C12N2740/16334
Abstract: The invention provides (a) an HIV Tat protein or derivative thereof linked to either (i) a fusion partner or (ii) an HIV Nef protein or derivative thereof; or (b) an HIV Nef protein or derivative thereof linked to either (i) a fusion partner or (ii) an HIV Tat protein or derivative thereof; or (c) an HIV Nef protein or derivative thereof linked to an HIV Tat protein or derivative thereof and a fusion partner. The invention further provides for a nucleic acid encoding such a protein and a host cell, such as Pichia Pastoris, transformed with the aforementioned nucleic acid.
-
Patent Agency Ranking
公开(公告)号：US20080089902A1
公开(公告)日：2008-04-17
申请号：US11866146
申请日：2007-10-02
Applicant: Claudine BRUCK , Stephane Godart , Martine Marchand
Inventor： Claudine BRUCK , Stephane Godart , Martine Marchand
CPC classification number: C07K14/005 , A61K39/00 , A61K39/12 , A61K39/21 , A61K2039/55572 , A61K2039/55577 , A61K2039/6068 , C07K2319/00 , C12N2740/16322 , C12N2740/16334
Abstract: The invention provides (a) an HIV Tat protein or derivative thereof linked to either (i) a fusion partner or (ii) an HIV Nef protein or derivative thereof; or (b) an HIV Nef protein or derivative thereof linked to either (i) a fusion partner or (ii) an HIV Tat protein or derivative thereof; or (c) an HIV Nef protein or derivative thereof linked to an HIV Tat protein or derivative thereof and a fusion partner. The invention further provides for a nucleic acid encoding such a protein and a host cell, such as Pichia Pastoris, transformed with the aforementioned nucleic acid.
Abstract translation: 本发明提供（a）与（i）融合伴侣或（ii）HIV Nef蛋白或其衍生物连接的HIV Tat蛋白或其衍生物; 或（b）与（i）融合伴侣或（ii）HIV Tat蛋白或其衍生物连接的HIV Nef蛋白或其衍生物; 或（c）与HIV Tat蛋白或其衍生物和融合配偶体连接的HIV Nef蛋白或其衍生物。 本发明进一步提供了用上述核酸转化的编码这种蛋白质和宿主细胞如毕赤酵母的核酸。
-
公开(公告)号：US20070299160A1
公开(公告)日：2007-12-27
申请号：US11659270
申请日：2004-09-21
Applicant: Jean-Luc Delanaye , Martine Marchand
Inventor： Jean-Luc Delanaye , Martine Marchand
IPC: C08J9/32
CPC classification number: C08L23/10 , C08L23/16 , C08L2205/20 , C08L2205/22 , C08L2312/00 , C08L2666/06
Abstract: Hollow microspherical, mineral or hard plastic, fillers are used to increase the insulation properties of thermoplastic olefin compositions, especially where used in extruded profiles, sheets or tapes. The thermoplastic olefins comprise a thermoplastic phase and a rubber phase wherein the rubber is at least partially cross-linked by dynamic vulcanization. The microspherical fillers can be added by melt blending with the pre-formed thermoplastic olefins. The natural wear-resistance, oxidative stability and thermal insulating properties of thermoplastic olefins, with the enhancement from the hollow microspheres make them particularly suitable for marine conduits, such as those used in the off-shore drilling industry in flexible pipelines, electrical cables and tethering lines.
Abstract translation: 空心微球，矿物或硬塑料填料用于增加热塑性烯烃组合物的绝缘性能，特别是在挤出型材，片材或胶带中使用时。 热塑性烯烃包括热塑性相和橡胶相，其中橡胶通过动态硫化至少部分交联。 可以通过与预成型的热塑性烯烃熔融共混来加入微球填料。 热塑性烯烃的天然耐磨性，氧化稳定性和绝热性能，随着中空微球的增强，使得它们特别适用于海洋管道，例如在柔性管道，电缆和束缚的离岸钻井工业中使用的那些 线条。
-
公开(公告)号：US20100184836A1
公开(公告)日：2010-07-22
申请号：US12578969
申请日：2009-10-14
Applicant: Helge ABRECHT , Martine Delchambre , Martine Marchand , Nathalie Louise Mathy , Philippe Jean Gervais Ghislain Permanne , Gerald Hermann Voss
Inventor： Helge ABRECHT , Martine Delchambre , Martine Marchand , Nathalie Louise Mathy , Philippe Jean Gervais Ghislain Permanne , Gerald Hermann Voss
IPC: A61K31/7088 , C07H21/04
CPC classification number: C07K14/005 , A61K2039/645 , C07K2319/00 , C12N2740/16222 , C12N2740/16322
Abstract: This invention relates to novel HIV polypeptide and polynucleotide fusions of Gag, Pol and Nef which are useful in immunogenic compositions and vaccines. The invention relates in particular to a polypeptide which comprises Nef or an immunogenic fragment thereof, and p17 Gag and/or p24 Gag or immunogenic fragments thereof, wherein when both p17 and p24 Gag are present there is at least one HIV antigen or immunogenic fragment between them. The polypeptide may also comprise Pol or RT or an immunogenic fragment thereof.
Abstract translation: 本发明涉及可用于免疫原性组合物和疫苗的Gag，Pol和Nef的新型HIV多肽和多核苷酸融合体。 本发明特别涉及包含Nef或其免疫原性片段和p17 Gag和/或p24 Gag或其免疫原性片段的多肽，其中当p17和p24 Gag都存在时，存在至少一种HIV抗原或免疫原性片段 他们。 多肽还可以包含Pol或RT或其免疫原性片段。
-
公开(公告)号：US20100215681A1
公开(公告)日：2010-08-26
申请号：US12767069
申请日：2010-04-26
Applicant: Claudine BRUCK , Stephane Andre Georges Godart , Martine Marchand
Inventor： Claudine BRUCK , Stephane Andre Georges Godart , Martine Marchand
CPC classification number: C07K14/005 , A61K39/00 , A61K39/12 , A61K39/21 , A61K2039/55572 , A61K2039/55577 , A61K2039/6068 , C07K2319/00 , C12N2740/16322 , C12N2740/16334
Abstract: The invention provides (a) an HIV Tat protein or derivative thereof linked to either (i) a fusion partner or (ii) an HIV Nef protein or derivative thereof; or (b) an HIV Nef protein or derivative thereof linked to either (i) a fusion partner or (ii) an HIV Tat protein or derivative thereof; or (c) an HIV Nef protein or derivative thereof linked to an HIV Tat protein or derivative thereof and a fusion partner. The invention further provides for a nucleic acid encoding such a protein and a host cell, such as Pichia Pastoris, transformed with the aforementioned nucleic acid.
Abstract translation: 本发明提供（a）与（i）融合伴侣或（ii）HIV Nef蛋白或其衍生物连接的HIV Tat蛋白或其衍生物; 或（b）与（i）融合伴侣或（ii）HIV Tat蛋白或其衍生物连接的HIV Nef蛋白或其衍生物; 或（c）与HIV Tat蛋白或其衍生物和融合配偶体连接的HIV Nef蛋白或其衍生物。 本发明进一步提供了用上述核酸转化的编码这种蛋白质和宿主细胞如毕赤酵母的核酸。
-
公开(公告)号：US20080089929A1
公开(公告)日：2008-04-17
申请号：US11866225
申请日：2007-10-02
Applicant: Claudine BRUCK , Stephane Andre Godart , Martine Marchand
Inventor： Claudine BRUCK , Stephane Andre Godart , Martine Marchand
CPC classification number: C07K14/005 , A61K39/00 , A61K39/12 , A61K39/21 , A61K2039/55572 , A61K2039/55577 , A61K2039/6068 , C07K2319/00 , C12N2740/16322 , C12N2740/16334
Abstract: The invention provides (a) an HIV Tat protein or derivative thereof linked to either (i) a fusion partner or (ii) an HIV Nef protein or derivative thereof; or (b) an HIV Nef protein or derivative thereof linked to either (i) a fusion partner or (ii) an HIV Tat protein or derivative thereof; or (c) an HIV Nef protein or derivative thereof linked to an HIV Tat protein or derivative thereof and a fusion partner. The invention further provides for a nucleic acid encoding such a protein and a host cell, such as Pichia Pastoris, transformed with the aforementioned nucleic acid.
-
-
-
-
-
-
-
-
-
Search Results
21
records
(took 0.021 seconds)
